MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into
Strategic Collaboration and Licensing Agreement for the Development ofPyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
San Diego, CA /Osaka, JPN/Gaithersburg, MD
September 23, 2015 – MedImmune, the global biologics research and development arm ofAstraZeneca, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi
Tanabe Pharma Corporation (MTPC), today announced that they have entered into a strategic
collaborationandlicensing

agreement

underwhichTRL

willuseMedImmune’s

pyrrolobenzodiazepine (PBD)-based warhead and linker technology to generate monospecific andbispecific antibody-drug conjugates (ADCs) for investigation in various cancers.
Under the agreement, TRL will exclusively license MedImmune’s next generation PBDs. The
companies will partner to combine MedImmune’s PBD technology with TRL’s antibodies to develop
next generation ADCs against a number of cancer targets.

MedImmune will receive an upfront

payment, development and commercial milestone payments, as well as single digit royalties on
worldwide net sales.
MTPC will be responsible for the pre-clinical research, development, manufacturing and later-stage
activities, including global commercialization.

MedImmune has the option to an exclusive license

for the development and commercialization of the programs in the United States and Europe at theconclusion of a Phase Ib trial.
ADCs are a developing area of cancer drug technology that offers selective targeting of cancer cells.
MedImmune’s proprietary PBD technology provides cytotoxic agents, or warheads, for attachment tospecific cancer-targeting antibodies. This targeted ADC approach has the potential to optimize thedelivery of the cancer drug to the tumor.

MedImmune has an active internal ADC pipeline withcandidates nearing the clinic, and TRL has an active program of mono- and bispecific-antibodies
targeting cancer cells.
“We are very pleased to join forces with MedImmune to further exploit our proprietary tumor specificantibodies,” said Naoki Sakurai, Ph.D, Chief Executive Officer, TRL. “This is an important start for ourpioneering work in the field of mono- and bi-specific therapeutic ADCs and we are excited to exploreinnovative therapeutic approaches in collaboration with one of the world’s leading biotech
companies,” added Roland Newman, Ph.D., Chief Scientific Officer, TRL.

Ronald Herbst, Vice President, Oncology Research & Development, MedImmune, said, “Developing
next generation antibody-drug conjugates, including our proprietary PBD technology, is one of ourkey strategic areas of focus in oncology. Today’s collaboration with Tanabe Research Laboratories
supports our efforts to grow our ADC portfolio through both internal activities and external
partnerships, with the goal of generating novel treatments to meaningfully improve the lives of cancerpatients.”###About Mitstubishi Tanabe Pharma Corporation (MTPC): MTPC is a research-driven pharmaceuticalcompany based in Osaka Japan, specializing in research, development and marketing of globallycompetitive pharmaceutical products focused on small molecule and biological therapeutics in avariety of fields. MTPC contributes to the healthier lives of people around the world through thecreation of pharmaceuticals.
http://www.mt-pharma.co.jp/eAbout Tanabe Research Laboratories U.S.A., Inc. (TRL): TRL is an independent subsidiary of MTPC
located in San Diego California, whose role is to discover and develop biological drug candidates fortherapy. Currently, TRL's efforts are directed towards antibody and antibody-related research totarget tumors and other diseases with high unmet needs. TRL is establishing collaborative
relationships with other companies and academic research organizations to further its goals ofidentifying preclinical therapeutic lead compounds for development.
http://www.trlusa.com/
About MedImmune:
MedImmune is the global biologics research and development arm of AstraZeneca. MedImmune ispioneering innovative research and exploring novel pathways across key therapeutic areas,including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease;oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in
Gaithersburg, Md., one of AstraZeneca’s three global R&D centres. For more information, please
visit https://www.medimmune.com/
Contact:Tracy Rossin
MedImmune
rossint@medimmune.com(301) 398-1468